Research on cancer immunotherapy effects of high-frequency hyperthermia cancer treatment device ‘REMISSION 1℃’ begins in earnest

AdipoLABs-Yonsei University (Wonju) MOU, expecting new hope for patients through proof of immune-related effects

▲ Lee Kang-hyun, Dean of Yonsei Wonju University (left), and AdipoLABs CEO Han Sung-ho are posing after signing an agreement.

【Whosaeng】  AdipoLABs Co., Ltd., leading the world's high-frequency hyperthermia cancer treatment device market, is joining hands with Yonsei Wonju Medical University to begin research on the cancer immunotherapy effects of 'REMISSION 1℃', a high-frequency hyperthermia cancer treatment device.

AdipoLABs (CEO Han Sung-ho) announced on the 27th that the company signed an MOU for cancer treatment research with Yonsei Wonju University (Dean Lee Kang-hyun) Christian Hospital.

AdipoLABs' high-frequency hyperthermia cancer treatment device 'REMISSION 1℃' is a pure domestic technology that was approved for use in cancer treatment by the Ministry of Food and Drug Safety in October 2015. It is safe due to the frictional heat of the resistance value generated by high-frequency waves penetrating the human body. It is a medical device that can raise body temperature up to 42℃ and perform both hyperthermia and immunotherapy.

REMISSION 1°C, which is currently being used in about 100 medical institutions in Korea, was introduced to the Catholic University of Korea's Seoul St. Mary's Hospital in January 2019 and has been used on patients, showing many clinical effects and attracting interest and attention from the medical community.

In particular, it is a globally verified medical device that received Halal certification, US FDA registration, ISO13485 certification, Shariah certification, and RoHS certification in 2018.

Under this agreement, the medical school will use ‘REMISSION 1℃’, which improves blood circulation and immunity, treats cancer, and relieves pain by using deep heat that raises body temperature above 40℃. Now, the medical school will conduct research not only to study the effectiveness of treatment for cancer patients, but also to prove the effectiveness of treatment related to immunity.

CEO Han Sung-ho said, “Despite the economic difficulties at home and abroad due to the COVID-19 pandemic in 2020, the efficacy of REMISSION 1℃ has ameliorated many patients, and Yonsei University College of Medicine in Wonju has high expectations for such treatment.” He added, “With this agreement, REMISSION 1℃ will prove the effectiveness of immunotherapy for many cancer patients. I hope this will provide new hope to many patients,” he emphasized.

Meanwhile, AdipoLABs' ‘REMISSION 1℃’ recently obtained MDA certification from the Malaysian Ministry of Health, and exports to Southeast Asian markets such as Malaysia are expected to begin in full force starting this year.

source: [후생신보] 고주파 온열암치료기 ‘리미션1℃’ 암 면역치료 효과 연구 본격화 (whosaeng.com)